GLP-1s & Weight Loss
Liraglutide
← Back to Library
Label-verified Label-verified Label-verified Incretin Metabolic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10, 20, 30 mg
Dosing window: Anytime
Receptor / target: GLP-1
Properties: Incretin
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 0.6mg daily | Initiation dose. |
| Week 2 | 1.2mg daily | Step up. |
| Week 3 | 1.8mg daily | Standard maintenance. |
| Week 4 | 2.4mg daily | Fat loss threshold. |
| Week 5+ | 3.0mg daily | Maximum weight loss dosage. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Protocol logic check
Protocol context: Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (GLP-1); route Subcutaneous; timing Anytime. Label/trial anchors carry more weight than forum-style escalation. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.
Independent evidence
Approved label dosing: Saxenda is injected SC once daily. Titration is 0.6 mg daily for week 1, then 1.2, 1.8, 2.4, and 3 mg daily at weekly intervals; 3 mg daily is the adult recommended dose.
Clinical trial regimen(s): SCALE Obesity and Prediabetes used liraglutide 3.0 mg daily plus lifestyle intervention for 56 weeks.
Regulatory status: approved drug label available
Storage
Follow Saxenda pen label storage; unopened pens are refrigerated and in-use storage/discard timing is product-specific.
Contraindications (limited evidence)
- Personal or family history of Medullary Thyroid Carcinoma (MTC). Limited / unverified
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Limited / unverified
- Personal or family history of thyroid C-cell tumors. Limited / unverified
- Active or history of acute pancreatitis. Limited / unverified
- Severe gastroparesis or clinically significant delayed gastric emptying. Limited / unverified
- Type 1 diabetes mellitus. Limited / unverified
- Diabetic ketoacidosis. Limited / unverified
- Severe renal impairment (eGFR < 30 mL/min/1.73m²) or end-stage renal disease: not recommended due to risk of dehydration-mediated acute kidney injury compounding existing impairment. Limited / unverified
- Severe hepatic impairment: limited safety data; use not recommended. Limited / unverified
- Pregnancy: animal studies show fetal harm; contraindicated; discontinue prior to planned conception. Limited / unverified
- Breastfeeding: excreted in animal milk; avoid use. Limited / unverified
- Known hypersensitivity or anaphylaxis to liraglutide or any formulation excipient. Limited / unverified
- Concurrent use with any other GLP-1 receptor agonist (e.g., semaglutide, exenatide, dulaglutide): overlapping mechanism; additive GI toxicity. Limited / unverified
- Concurrent use with any dual/triple incretin agonist: direct pharmacological conflict. Limited / unverified
- Concomitant use of insulin or insulin secretagogues without dose reduction: significantly elevated hypoglycemia risk. Limited / unverified
- Concomitant use of warfarin or oral medications with narrow therapeutic index: daily GI motility changes alter absorption kinetics. Limited / unverified
- History of suicidal ideation or prior suicide attempts: monitor closely; behavioral changes reported in post-marketing data. Limited / unverified
- Planned general anesthesia or elective surgery: delayed gastric emptying raises pulmonary aspiration risk; follow pre-operative fasting protocols. Limited / unverified
- Pediatric use under age 12 (Victoza) or under age 12 for obesity (Saxenda): safety not established below approved age thresholds. Limited / unverified
- Heart failure (NYHA Class IV): insufficient clinical data. Limited / unverified
Side effects (limited evidence)
- Nausea: most prevalent adverse effect; higher daily incidence than weekly agents due to constant receptor stimulation without peak/trough cycle; reported in up to 40% of subjects. Limited / unverified
- Vomiting. Limited / unverified
- Diarrhea. Limited / unverified
- Constipation. Limited / unverified
- Abdominal pain and cramping. Limited / unverified
- Dyspepsia (indigestion). Limited / unverified
- Abdominal distension and bloating. Limited / unverified
- Decreased appetite and dysgeusia (altered taste). Limited / unverified
- Belching and flatulence. Limited / unverified
- Gastroparesis: delayed gastric emptying; clinically relevant for anesthesia planning. Limited / unverified
- Gastroesophageal reflux disease (GERD) exacerbation. Limited / unverified
- Injection site reactions: pain, erythema, bruising, and nodule formation; more pronounced than weekly agents due to daily injections cycling through limited rotation sites. Limited / unverified
- Injection site fatigue: daily dosing exhausts viable injection site rotation faster than weekly protocols. Limited / unverified
- Fatigue and lethargy: frequently secondary to caloric deficit. Limited / unverified
- Headache. Limited / unverified
- Dizziness. Limited / unverified
- Hypoglycemia: rare in monotherapy; significant risk when combined with insulin or sulfonylureas. Limited / unverified
- Acute pancreatitis: class risk; rare but documented; discontinue if severe upper abdominal pain develops. Limited / unverified
- Acute kidney injury: primarily dehydration-mediated from GI fluid losses; monitor renal function in at-risk subjects. Limited / unverified
- Cholelithiasis (gallstones) and acute cholecystitis: risk increases with dose and duration. Limited / unverified
- Diabetic retinopathy complications: risk elevated in subjects with pre-existing retinopathy during rapid glycemic correction. Limited / unverified
- Thyroid C-cell tumor risk: confirmed in rodent models; human risk not definitively established; monitor for neck mass, hoarseness, dysphagia, or dyspnea. Limited / unverified
- Increased heart rate: modest mean increase of 2-3 BPM; less pronounced than glucagon-containing compounds. Limited / unverified
- Alopecia (hair loss): reported in post-marketing surveillance. Limited / unverified
- Anaphylaxis and angioedema: rare but documented. Limited / unverified
- Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying. Limited / unverified
- Reduced compliance over time: daily injection burden is the primary driver of protocol non-adherence compared to weekly alternatives. Limited / unverified
- Rapid weight regain upon discontinuation: similar to other GLP-1 agents; expected without lifestyle maintenance. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: